Genetics
Familial
melanoma is genetically heterogeneous, and loci for familial melanoma
have been identified on the chromosome arms 1p, 9p and 12q. Multiple
genetic events have been related to the pathogenesis of melanoma. The
multiple tumor suppressor 1 (CDKN2A/MTS1) gene encodes p16INK4a - a
low-molecular weight protein inhibitor of cyclin-dependent protein kinases
(CDKs) - which has been localised to the p21 region of human chromosome
9. Today, melanomas are diagnosed only after they become visible on
the skin. In the future, however, physicians will hopefully be able
detect melanomas based on a patient’s genotype, not just his or
her phenotype. Recent genetic advances promise to help doctors to identify
people with high-risk genotypes and to determine which of a person’s
lesions have the greatest chance of becoming cancerous. A number of
rare mutations, which often run in families, are known to greatly increase
one’s susceptibility to melanoma. One class of mutations affects
the gene CDKN2A. An alternative reading frame mutation in this gene
leads to the destabilization of p53, a transcription factor involved
in apoptosis and in fifty percent of human cancers. Another mutation
in the same gene results in a non-functional inhibitor of CDK4, a [cyclin-dependent
kinase] that promotes cell division. Mutations that cause the skin condition
Xeroderma Pigmentosum (XP) also seriously predispose one to melanoma.
Scattered throughout the genome, these mutations reduce a cell’s
ability to repair DNA. Both CDKN2A and XP mutations are highly penetrant.
Other mutations confer lower risk but are more prevalent in the population.
People with mutations in the MC1R gene, for example, are two to four
times more likely to develop melanoma than those with two wild-type
copies of the gene. MC1R mutations are very common; in fact, all people
with red hair have a mutated copy of the gene. Two-gene models of melanoma
risk have already been created, and in the future, researchers hope
to create genome-scale models that will allow them to predict a patient’s
risk of developing melanoma based on his or her genotype. In addition
to identifying high-risk patients, researchers also want to identify
high-risk lesions within a given patient. Many new technologies, such
as optical coherence tomography (OCT), are being developed to accomplish
this. OCT allows pathologists to view 3-D reconstructions of the skin
and offers more resolution than past techniques could provide. In vivo
confocal microscopy and fluorescently tagged antibodies are also proving
to be valuable diagnostic tools.